The Elec EnglishDoubao · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 06:31:53(首尔 07:31)时区推断·⟳ 抓取 06:32:59·⚡ 决策 09-15 06:34:53 +1m54s·42.6 天前
柳韩洋行WCLC海报仅披露YH42946口服HER2 TKI的I/II期试验设计与进度，疗效数据要等年底
按生物医药阶段-权益框架，本次海报把资产留在『I期进行中』状态，未完成任何状态迁移：无人体疗效/安全性读出、无监管节点、无授权交易，且资产对大市值柳韩洋行不具materiality；韩文媒体已于首尔时间9月14日午间广泛报道，英文稿属同日延后扩散。
📄 原文The Elec English↗ 原文
Yuhan Reports Phase 1/2 Progress for Lung Cancer Drug Candidate
Yuhan Corp. presented an update on the Phase 1/2 development of YH42946, a drug candidate for lung cancer. Yuhan said M…
不做 Yuhan Corporation（柳韩洋行）（000100.KS）
WCLC海报仅为I/II期试验设计与入组进度更新，无人体疗效/安全性读出、无授权交易，属早期研发常规披露；韩文媒体当日已广泛报道，对大市值公司无materiality，无短线edge；等待2026年底首批临床数据作为独立事件再评估
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
YH42946在WCLC只公布I/II期试验设计、入组进度和临床前活性，首批临床数据要到2026年底；早期研发进度更新对柳韩洋行（000100.KS）这类大市值药企无短线业绩或估值增量，也无跨市场权益映射，不构成可交易催化。
消息传播链
- 最早可见报道，引用WCLC现场海报内容与年底出数据时间表；原始一手节点为WCLC 2026现场poster，非交易所披露
- 补充Part 1入组53人、23人持续治疗、2027年剂量优化计划等细节
- 英文财经媒体当日下午已覆盖，说明消息在韩国本土交易时段前已完成扩散
- 本信号英文稿，时间戳相当于首尔9月15日07:32，为韩文报道的英文延后转写，无新增事实
关键理由
- 无做多依据：仅I期设计/进度披露+临床前数据，按状态迁移表资产仍处『临床前→I期』早期阶段，真正催化是年底人体数据读出
主要风险
- 若后续年底I期数据超预期或出现对外授权大单，需作为独立新事件重新评估，不能把本次海报当作前置利好抢跑
反向证据
- 做多前查反向 · 来源 web · 日期 2026-09-14 · 影响 invalidates
未发现任何授权交易、人体疗效阳性结果或监管突破；全部同日报道均限于试验设计与临床前数据，做多催化不成立
检索:Yuhan YH42946 license deal partnership efficacy data WCLC 2026 原文 ↗
先例如何影响了这次决策
对本次决策的影响:未因任何先例调仓；结论直接由阶段-权益分析与新鲜度得出
方向:未用先例定价：事件在状态迁移层面即无增量（I期设计海报，无人体读出），方向与edge不成立，先例幅度不影响AVOID结论
涨幅量级:无合格对齐样本；早期肿瘤管线『仅试验设计/进度海报』对大市值药企通常不产生系统性事件收益
形态:未进行event_study回测；此类无读出海报不具备可交易的事件窗口
工具执行结果 · 成功 3 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 15 ms
{"result": "search_processed_events:agent query=`yuhan corp first-in-human yh42946 poster world conference on lung cancer | yuhan yh42946 her2 oral tki lung cancer wclc 2026 phase 1/2 | 유한양행 yh4294646 her2 폐암 wclc 2026`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式 - fetch_decision_experience 成功 stock_tools HTTP · 9 ms
{ - web_search 成功 doubao_search · 1,474 ms
豆包搜索结果（原始查询:Yuhan YH42946 HER2 TKI lung cancer WCLC 2026 Phase 1 partner license；API SearchType:web）
原文全文
展开原文 · 1,571 字
Yuhan Corp. presented an update on the Phase 1/2 development of YH42946, a drug candidate for lung cancer.
Yuhan said Monday it presented the design and progress of its first-in-human Phase 1/2 study of YH42946, an oral targeted therapy candidate against human epidermal growth factor receptor 2 (HER2), at the 2026 World Conference on Lung Cancer (WCLC) being held at COEX in Seoul. The data were presented as a poster.
YH42946 is an oral small-molecule tyrosine kinase inhibitor (TKI) targeting HER2, a protein involved in the proliferation of cancer cells.
The candidate showed strong antitumor activity in preclinical tumor models involving HER2 amplification and overexpression, as well as specific mutations, including epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
The Phase 1/2 trial combines Phase 1 and Phase 2 studies and is being conducted concurrently. Phase 1 evaluates a safe dose range and adverse effects, while Phase 2 administers the treatment to a larger number of patients to explore its efficacy, including whether it can reduce tumors.
Phase 1/2 development combines the first two stages of clinical testing and is commonly used for drug candidates where development speed is important. It can shorten the overall development timeline compared with conducting each clinical stage separately.
Existing treatments are administered intravenously or have limited use because of toxicity concerns. Brain metastases are also common among the relevant patient population, creating strong demand for effective oral targeted therapies.
Yuhan said Monday it presented the design and progress of its first-in-human Phase 1/2 study of YH42946, an oral targeted therapy candidate against human epidermal growth factor receptor 2 (HER2), at the 2026 World Conference on Lung Cancer (WCLC) being held at COEX in Seoul. The data were presented as a poster.
YH42946 is an oral small-molecule tyrosine kinase inhibitor (TKI) targeting HER2, a protein involved in the proliferation of cancer cells.
The candidate showed strong antitumor activity in preclinical tumor models involving HER2 amplification and overexpression, as well as specific mutations, including epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
The Phase 1/2 trial combines Phase 1 and Phase 2 studies and is being conducted concurrently. Phase 1 evaluates a safe dose range and adverse effects, while Phase 2 administers the treatment to a larger number of patients to explore its efficacy, including whether it can reduce tumors.
Phase 1/2 development combines the first two stages of clinical testing and is commonly used for drug candidates where development speed is important. It can shorten the overall development timeline compared with conducting each clinical stage separately.
Existing treatments are administered intravenously or have limited use because of toxicity concerns. Brain metastases are also common among the relevant patient population, creating strong demand for effective oral targeted therapies.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。